Biotech Stocks
The latest news, updates and opinions on Biotech Stocks from the expert team here at MoneyWeek
Latest
-
Vexing vaccine delays hit drug firms
News AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
By Dr Matthew Partridge Published
News -
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
News AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge reports
By Dr Matthew Partridge Published
News -
The lessons of “Operation Warp Speed” – the race to produce a vaccine
Opinion Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.
By Matthew Lynn Published
Opinion -
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
Podcasts The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think they are, and how our extended lockdown could have permanently changed our way of life. Plus, he picks one health-focused value stock to buy now.
By moneyweek Published
Podcasts -
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Opinion Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
By Matthew Lynn Published
Opinion -
More good news as AstraZeneca finds a third Covid vaccine
News Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge reports
By Dr Matthew Partridge Published
News -
Moderna’s “stunning” second vaccine
News America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
By Dr Matthew Partridge Published
News -
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
Briefings A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be cheerfully optimistic, says Simon Wilson.
By Simon Wilson Published
Briefings -
How to profit from the development of new auto-immune disease drugs
Tips Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals market.
By Dr Mike Tubbs Published
Tips